Find Academic Supervisors

Tatiana GoretskyView profile

Assistant Professor

• Inflammatory Bowel Disease (IBD)
• Gastrointestinal Physiology
• Epithelial Cell Signaling
• +7 more

Tatiana Goretsky, PhD, is an Assistant Professor in the Department of Internal Medicine at the University of Kentucky College of Medicine, with a focus on Digestive Health and Nutrition. Her research is centered on the molecular mechanisms underlying inflammatory bowel disease (IBD), epithelial cell signaling, and mucosal repair. Education: Masters in Physiology of Animals and Humans, Lomonosov State University, Moscow, Russia PhD in Biochemistry, Russian Academy of Sciences, Pushchino, Moscow Region, Russia Her research interests span Inflammatory Bowel Disease , β-catenin and NF-kappaB signaling , mitochondrial function in the gut , and epithelial cell apoptosis and regeneration . Her work integrates molecular biology, cell signaling, and translational gastroenterology to understand disease pathogenesis and identify therapeutic targets. Analysis of her recent publications reveals a strong focus on signaling pathways such as PI3K, β-catenin, and TNF in the context of intestinal injury, repair, and cancer. Her studies frequently explore how dysregulation of these pathways contributes to IBD and colitis-associated neoplasia, with emerging work on mitochondrial metabolism and microbiome interactions. Scientific Contributions: Investigated β-catenin cleavage and activation in colitis Elucidated roles of p53 and PHLPP in epithelial apoptosis Demonstrated TNF receptor signaling in mucosal repair Explored mitochondrial function in IBD pathogenesis Examined PI3K signaling in radiation-induced gut injury Dr. Goretsky actively collaborates with Dr. Terrence A. Barrett and other researchers in gastrointestinal pathobiology. While no formal advisees are listed, her publications suggest mentorship roles in collaborative research. She has no publicly listed scientific awards in the provided text. Her lab likely focuses on epithelial signaling mechanisms in digestive diseases, contributing to the broader mission of the Digestive Health and Nutrition division at UK.

• Cartilage Repair
• Stem Cell Biology
• Osteoarthritis
• +3 more

Anke Roelofs is an Honorary Senior Lecturer affiliated with the School of Medicine, Medical Sciences and Nutrition. Her research focuses on regenerative medicine, stem cell biology, and musculoskeletal disorders, particularly osteoarthritis and cartilage repair. She investigates the molecular mechanisms underlying synovial fibroblast behavior, stem cell therapies, and the role of adipose tissue in joint health. Her work spans preclinical drug evaluations (e.g., Lorecivivint), immunological pathways (e.g., IL-6/PD-L1 interactions), and lipidomic profiling in joint tissues. Roelofs has contributed to understanding BMP signaling's role in osteoarthritis and the therapeutic potential of mesenchymal stromal cells. Her research highlights the interplay between inflammation, cell lineage hierarchies, and tissue regeneration. Recent studies emphasize mechano-activated chondroprogenitors and synovial joint progenitors as targets for regenerative therapies. She employs advanced techniques like single-cell resolution analysis and fluorescent bisphosphonate imaging to study cellular pathways and drug delivery mechanisms in skeletal tissues. Awards and grants are not explicitly mentioned in the provided texts, but her extensive publication record reflects sustained contributions to joint biology and regenerative strategies. Roelofs collaborates on translational research, bridging basic science with clinical applications in musculoskeletal disorders.

Gianrico FarrugiaView profile

Professor

• Enteric Neurosciences
• Gastrointestinal Motility
• Ion Channel Physiology
• +5 more

Gianrico Farrugia, M.D., is a Professor of Medicine and Physiology at Mayo Clinic, where he serves as Director of the Enteric Neuroscience Program. He holds the John H. Noseworthy and Jay Alix Distinguished Chair and is a leader in gastrointestinal motility research. His lab focuses on understanding cellular and molecular mechanisms underlying disorders like diabetic gastroparesis, slow transit constipation, and irritable bowel syndrome. Education: Completed medical training at the Royal University of Malta and advanced fellowships in physiology and gastroenterology at Mayo Clinic. Holds academic appointments in both Internal Medicine and Physiology & Biomedical Engineering. Research Interests: His work spans ion channel physiology, interstitial cells of Cajal, and the role of carbon monoxide in gut function. Recent studies include mechanisms of diabetic gastroparesis (linking M2 macrophage dysfunction to interstitial cell loss) and targeted therapies for sodium channel mutations in IBS. Techniques include high-resolution imaging, next-gen sequencing, and cellular models. Grants & Awards: Active NIH grants since 1997; received 2019 NGM Research Mentor Award and multiple academic honors. Leads the Mayo Center for Cell Signaling in Gastroenterology and collaborates with the NIDDK Gastroparesis Clinical Research Consortium. Labs & Teams: Heads the Cellular and Molecular Physiology of Gastrointestinal Disorders Lab, collaborating with the Enteric Neuroscience Program and international motility societies. Trains postdoctoral fellows in translational research.

David BriscoeView profile

Professor

• Transplantation Immunology
• Chronic Allograft Rejection
• Pediatric Transplantation
• +12 more

Dr. David Briscoe is a Professor of Pediatrics at Harvard Medical School and holds the Casey Lee Ball Chair in Transplantation at Boston Children's Hospital. He leads the Briscoe Lab and serves as Director of the Transplant Research Program, focusing on chronic allograft rejection and transplantation immunology. His research bridges basic science and clinical translation to improve long-term outcomes in pediatric organ transplantation. Professor of Pediatrics, Harvard Medical School Casey Lee Ball Chair in Transplantation, Boston Children's Hospital Director, Transplant Research Program Principal Investigator, T32 Training Grant (funded through 2025) Senior Editor, Transplantation Direct Dr. Briscoe earned his medical degree at the Royal College of Surgeons in Ireland and completed residency training in General Medicine and Pediatrics in Dublin, followed by Pediatric Residency at the University of Colorado and a postdoctoral fellowship in Pediatric Nephrology at Boston Children’s Hospital and Harvard Medical School. His research focuses on the intragraft microenvironment, endothelial-immune interactions, T cell regulation, and biomarker development. He investigates how leukocyte-endothelial crosstalk and signaling pathways like mTOR and chemokines influence chronic rejection. His lab applies discoveries to develop novel therapeutics and transformative care initiatives, particularly in pediatric transplantation. The 15 most recent publications (2015–2025) reveal a strong emphasis on immune monitoring using microfluidics, chemokine profiling, endothelial immunomodulation, and mTOR signaling. Key themes include subclinical rejection detection, autophagy in post-transplant cancer, and inflammation resolution mechanisms. His work integrates immunology, vascular biology, and translational engineering to advance personalized care. Among his honors are the Young Investigator Award and Basic Science Investigator Award from the American Society of Transplantation, and election to the American Society of Clinical Investigation. Young Investigator Award, American Society of Transplantation Basic Science Investigator Award, American Society of Transplantation Elected Member, American Society of Clinical Investigation Dr. Briscoe has been Principal Investigator of an NIH T32 training grant since 2008, mentoring postdoctoral fellows and supporting physician-scientist training. He has also held multiple NIH R01 grants supporting discovery-based research. He serves on NIH study sections and editorial boards, advocating for translational research and education in transplantation science. He leads the Briscoe Lab, which investigates the molecular basis of chronic rejection, and directs the Transplant Research Program at Boston Children’s Hospital. The program fosters innovation through interdisciplinary research on alloimmune responses, novel signaling pathways, and clinical translation to improve pediatric transplant outcomes.

• Nephrology
• Medical Imaging
• Oncology
• +5 more

Dominik Kylies is an academic physician-scientist at the University Medical Center Hamburg-Eppendorf, affiliated with the Faculty of Medicine and Department of Nephrology. His research spans multiple disciplines including nephrology, oncology, and medical imaging, with a particular focus on kidney diseases, cancer-related complications, and advanced diagnostic techniques. As evidenced by his publication record, Dr. Kylies collaborates extensively with researchers across multiple institutions and contributes significantly to translational medical research. Dr. Kylies' research interests primarily center on nephrology with specific focus areas including membranous nephropathy, complement system activation, kidney organoid modeling, and the intersection of kidney disease with cancer. His work also extends to sarcopenia and body composition analysis in cancer patients, particularly examining how muscle wasting affects outcomes in multiple myeloma and osteosarcoma. Additionally, he investigates the role of the microbiome in cancer treatment efficacy and explores advanced imaging techniques for pathology specimen analysis. Analysis of Dr. Kylies' publication trends reveals a strong focus on translational research bridging basic science and clinical applications. His work spans kidney disease mechanisms, cancer complications, and advanced diagnostic methodologies. Recent publications demonstrate increasing sophistication in multi-omics approaches, spatial biology techniques, and super-resolution imaging. The research shows particular strength in connecting molecular mechanisms (like complement activation or microbiome metabolites) with clinical outcomes in nephrology and oncology. Dr. Kylies has contributed to significant advancements in understanding kidney disease mechanisms, particularly regarding complement system activation in membranous nephropathy and the role of collagen IV modifications in thin basement membrane disease. His work on sarcopenia in cancer patients has provided important clinical insights for risk stratification in stem cell transplantation. The development of optimized protocols for multiomics processing of kidney tissue represents a technical advancement in the field. Dr. Kylies collaborates with major research groups including the Center for Inflammation, Infection and Immunity (C3i) and the University Cancer Center Hamburg (UCCH). His research appears to be supported by institutional resources at the University Medical Center Hamburg-Eppendorf, including access to Core Facilities and the Research Information System. His extensive publication record suggests involvement in multiple collaborative research projects across nephrology, oncology, and immunology domains. Dr. Kylies is affiliated with the Third Medical Clinic and Polyclinic at UKE, which houses specialized research facilities for nephrology and internal medicine. His work appears connected to multiple research networks including the Cardiovascular Research Center (CVRC) and the Center for Health Care Research & Public Health. The collaborative nature of his publications suggests active participation in interdisciplinary research teams focused on kidney disease mechanisms and cancer-related complications.

• Cystic Fibrosis
• Primary Ciliary Dyskinesia
• Rhinology
• +5 more

Virginie Escabasse is a Professor in the Department of ENT at the University of Paris Est Créteil, France. She is actively engaged in research and clinical work focusing on cystic fibrosis, primary ciliary dyskinesia, and rhinology in both children and adults. Her research interests lie at the intersection of otolaryngology and respiratory medicine, particularly in mucociliary disorders. She investigates the pathophysiology of ciliary dysfunction, inflammatory responses in nasal epithelia, and potential therapeutic agents such as specialized pro-resolving mediators. Her work bridges molecular mechanisms with clinical outcomes. The trends in her recent publications highlight a strong focus on cystic fibrosis and primary ciliary dyskinesia, particularly in sinonasal manifestations and ciliary dynamics. She integrates molecular biology with clinical studies, including prognostic assessments in viral infections like COVID-19. She has collaborated with numerous researchers across pneumology and ENT departments, though no formal awards are mentioned in the provided text. Virginie Escabasse contributes to multidisciplinary patient care through reference centers for rare respiratory diseases. Her work is supported by collaborative networks across France, particularly in the management of chronic rhinosinusitis and genetic respiratory conditions.

• Immunology
• Virology
• Molecular Biology
• +7 more

Thomas Balligand is a researcher at the Namur Research Institute for Life Sciences, with significant contributions in immunology, virology, and nanobody engineering. His work spans both basic and translational research, focusing on novel therapeutic strategies against influenza viruses and cancer. He has strong collaborative ties with institutions such as Boston Children's Hospital and Harvard Medical School. Research Interests: Dr. Balligand's research is centered on the development of nanobody-based therapeutics. He investigates how engineered nanobodies—often derived from alpacas—can neutralize influenza viruses by targeting conserved regions like the hemagglutinin stem or immunoglobulin light chains. His work also extends to cancer immunotherapy, where he explores CAR NK cells armed with nanobodies targeting MICA+ tumors. Additionally, he contributes to structural studies of receptor mutants involved in oncogenesis, such as the thrombopoietin receptor. Publication Trends: Over the past decade, his research output has increasingly focused on engineered biologics for disease intervention. The most recent publications (2023–2025) highlight dual-function therapeutics, in vivo imaging tools, and structural insights into receptor activation. These works appear in high-impact journals such as Science Immunology , PNAS , and eLife , indicating strong scientific recognition. Scientific Awards: No specific awards are listed in the provided text. Advising and Grants: While no formal students are listed, his involvement in a doctoral thesis suggests mentorship activity. His research is likely supported by grants related to virology, immunology, and translational medicine, given the nature of his projects and institutional affiliations. Labs and Teams: Dr. Balligand is part of a collaborative network involving the Ploegh lab (known for nanobody and immune engineering) and works with teams specializing in molecular imaging, cancer immunotherapy, and structural biology. His use of congenic mouse models and PET imaging indicates access to advanced preclinical research infrastructure.

• Neuroblastoma
• Medulloblastoma
• Childhood Cancer
• +5 more

Marie Arsenian Henriksson is a Professor and Academic Vice President at Karolinska Institutet, leading the "Neural differentiation as a strategy for neuroblastoma treatment" research group within the Department of Microbiology, Tumor and Cell Biology. Her work focuses on neuroblastoma, the most common extra-cranial solid tumor in children that causes the highest number of cancer-related deaths in infants, as well as medulloblastoma tumors. Her research primarily investigates the role of the MYCN oncogene, which is amplified in high-risk neuroblastoma patients and strongly associated with poor survival and an undifferentiated tumor phenotype. A key discovery from her group demonstrated that the MYCN-regulated miR-17~92 cluster targets multiple nuclear hormone receptors, with the glucocorticoid receptor (GR) emerging as particularly significant. They found that GR is a direct target of this miRNA cluster, is the most significantly downregulated nuclear hormone receptor in MYCN-amplified neuroblastoma, and shows high prognostic value for patient outcomes. Her research has revealed that low GR expression correlates with an undifferentiated phenotype and decreased patient survival. Importantly, her team showed that MYCN inhibition and subsequent reactivation of GR signaling promotes neural differentiation and reduces tumor burden. This work provides a potential differentiation-based therapeutic approach for treating neuroblastoma patients. Her research group has received substantial funding from numerous sources including the Swedish Research Council, Swedish Cancer Society, Swedish Childhood Cancer Foundation, Knut and Alice Wallenberg Foundation, and other major Swedish research organizations. Knut and Alice Wallenberg Grant for over 30M SEK (2016) Featured researcher of the month at The Swedish Childhood Cancer Foundation (2015) Professor Henriksson supervises multiple PhD students and maintains collaborations with both national and international research groups. Her work aims to translate basic molecular discoveries into novel therapeutic strategies for childhood cancers, with potential applications extending to other MYC-driven cancers.

• Molecular Biology
• Genetics
• Cardiogenetics
• +12 more

Susana Santos is an Assistant Professor at Universidade Lusófona de Humanidades e Tecnologias, where she has taught Genetics, Molecular Biology, and Biotechnology since 2009. Her academic foundation was built at the University of Lisbon, where she earned her degree in Genetics and Microbiology and completed her Ph.D. in Molecular Biology, followed by a postdoctoral fellowship at the Faculty of Pharmacy, focusing on cardiovascular genetics. Her research spans a broad range of fields, including cardiogenetics, cancer biology, genomics, and biotechnology . She has coordinated the national Cardiogenetics project and contributed to over 10 national research initiatives. Her work bridges fundamental science and clinical applications, particularly in genetic diagnostics and therapeutic innovation. The analysis of her recent publications reveals a strong trend toward translational medicine , starting with cardiovascular and cancer genomics and evolving into novel biotechnological applications, including phytocannabinoids, terpenes, and gold-nanobeacons for gene therapy. Her research increasingly integrates computational and molecular approaches to develop innovative health solutions. Susana Santos has held leadership roles in biotechnology, co-founding HeartGenetics in 2013 and serving as Chief Innovation Officer at EXMceuticals Portugal since 2019. She is actively involved in developing cannabis-based therapeutics for healthcare and wellness. Her academic and professional journey reflects a deep commitment to applying genetic and molecular knowledge to real-world health challenges, from diagnostics to therapeutic development.

Jonathan WorboysView profile

Research Fellow

• Immunology
• Cell biology
• Proteomics
• +4 more

Jonathan Worboys is a Wellcome Trust Research Fellow at the University of Manchester, affiliated with the Lydia Becker Institute of Immunology and Inflammation and the Division of Immunology, Immunity to Infection & Respiratory Medicine. He holds a PhD in Cancer Biology (2015) from the Institute of Cancer Research (University of London) and a BSc in Biology with a Year in Europe from Imperial College London (2010). PhD: Cancer Biology, Institute of Cancer Research (2015) BSc: Biology with a Year in Europe, Imperial College London (2010) His research investigates how spatial organization of immune receptors governs their function, focusing on immune checkpoints—proteins that regulate immune responses and are critical in cancer immunotherapy. Current therapies targeting these checkpoints lack refinement, and his work aims to improve their efficacy. His recent studies explore TIGIT receptor dynamics, NLRP3 inflammasome regulation, and super-resolution microscopy applications. He received the 2024 Research Staff Excellence Award and leads an 8-year Wellcome Trust-funded project on nanoscale immune checkpoint governance. Expertise spans immunology , cell biology , super-resolution microscopy , and mass spectrometry . His work contributes to SDG-related research in health and well-being through immune signaling advancements.

• Nanomedicine
• Neuroscience
• Biomedical Engineering
• +3 more

Jinyoung Kang is a Researcher at the McGovern Institute for Brain Research, Massachusetts Institute of Technology (MIT). Their work focuses on developing advanced nanotechnology-based tools for biomedical applications, particularly in neuroscience and regenerative medicine. Kang's research emphasizes nanoparticle engineering, expansion microscopy techniques, and targeted drug delivery systems to address challenges in brain disorders, cancer therapy, and tissue repair. Key research interests include: Design of biocompatible porous silicon nanoparticles for therapeutic delivery Super-resolution imaging through expansion microscopy to visualize brain nanostructures Development of multifunctional nanomaterials for simultaneous diagnosis and treatment Optimization of drug release kinetics for targeted therapies Publications from 2020-2024 highlight Kang's contributions to neuroimaging innovations, tumor-targeted therapies, and regenerative biomaterials. The research demonstrates a strong emphasis on translating nanotechnology into clinical applications for conditions like rheumatoid arthritis, traumatic brain injury, and ovarian cancer. While no specific awards are listed, their work reflects impactful contributions to the fields of nanomedicine and biomedical engineering. Current affiliations include the McGovern Institute's neuroscience programs, with active collaborations in MIT's Department of Brain and Cognitive Sciences. No advising roles or grants are explicitly mentioned in the provided information.

• Biochemistry
• Cell Biology
• Medical Biochemistry
• +3 more

Professor David Carling is a Professor of Biochemistry at the Institute of Clinical Sciences within Imperial College London's Faculty of Medicine. He leads the Cellular Stress Group at the MRC London Institute of Medical Sciences and has held this position since 1990. His research focuses on the role of AMP-activated protein kinase (AMPK) in metabolic regulation, particularly its implications for obesity, cancer, and metabolic diseases. Affiliations include the Centre for Translational Nutrition and Food Research, the Immuno-Pathology Network, and the Vascular Science Network. David Carling holds a PhD from the University of Dundee (1987) and a BSc from the University of Bristol (1984). His work combines molecular, cellular, and systems approaches to investigate how metabolic dysregulation drives disease. Key research themes include AMPK's role in inflammation, fibrosis, and cancer, as well as its potential as a therapeutic target. His publications span mechanisms of AMPK activation, metabolic pathways in cancer, and the interplay between energy sensing and immune responses. Notable studies explore how AMPK modulates macrophage function, suppresses tumor growth, and corrects non-alcoholic fatty liver disease. His findings highlight AMPK's versatility as a regulator of diverse biological processes. Carling’s research has contributed to drug development targeting metabolic pathways, with implications for diabetes, atherosclerosis, and neuroblastoma. His interdisciplinary approach bridges basic science and translational medicine, emphasizing the clinical relevance of metabolic mechanisms.

• Atherosclerosis Research
• Macrophage Biology
• Systems Biology
• +3 more

Professor Joseph Boyle is a Professor of Chemical Systems Pathology at the National Heart and Lung Institute, Imperial College London, within the Faculty of Medicine. His research focuses on gene regulation in macrophages related to atherosclerosis, integrating systems biology, pharmacology, and clinical translation. He holds affiliations with the Immuno-Pathology Network, Vascular Science Network, and Vasculitis Centre. Trained as a histopathologist (FRCPath), he combines clinical expertise with laboratory research in vascular biology. Education: BSc (Hons) Pharmacology (University of Glasgow, 1988), MBChB (Glasgow, 1991), PhD (University of Cambridge, 1997–2001). Professional milestones include histopathology training (1992–2001) and postdoctoral fellowships at Imperial College London. Research interests emphasize protective gene regulation in macrophages, leveraging spatial transcriptomics and imaging technologies. His work spans drug development (e.g., metformin’s anti-atherosclerotic effects), enzyme-based probes (HO-1 detection), and immune responses in cardiovascular disease. Awards include the University of Glasgow Pharmacology Prize and FRCPath certification. Key contributions include identifying roles of SMARCA4, ATF1, and AMPK in macrophage function, and developing molecular imaging tools for atherosclerosis. His lab explores translational applications of these findings in diagnostics and therapeutics.

Hernandez Moura SilvaView profile

Assistant Professor

• Immunology
• Tissue Physiology
• Metabolic Syndrome
• +3 more

Hernandez Moura Silva is an Assistant Professor of Biology at MIT and a Core Member of the Ragon Institute of MGH, MIT & Harvard. His research focuses on immune-related pathways modulating organ and tissue physiology to develop therapeutic strategies for human diseases. His lab, the Laboratory of ImmunoPhysiology, employs an interdisciplinary approach to study macrophage biology and immune-tissue interactions. Education: PhD in Biology from the University of São Paulo (2011), MSc in Molecular Biology from the University of Brasilia (2008), and BS in Biology from the University of Brasilia (2005). Research Interests: Immunology, Tissue Physiology, Metabolic Syndrome, Inflammatory Disease, Macrophage Biology, and Immunotherapy. His work emphasizes how immune cells like macrophages maintain tissue homeostasis and contribute to pathologies like obesity, metabolic syndrome, and cancer. Notable Awards: 2012 CAPES Thesis Award (Brazil). Grants & Collaborations: His work is supported by initiatives like the HHMI Freeman Hrabowski Scholar program. He collaborates widely, evidenced by co-authored studies on topics like p53 mutation effects in pancreatic cancer and Th17 cell regulation. Labs/Teams: Leads the ImmunoPhysiology Lab at MIT, integrating immunology, physiology, and systems biology to study immune-tissue interfaces.

Andrei MaiseyeuView profile

Associate Professor

• Molecular Imaging
• Cardiovascular Disease
• Nanotechnology
• +7 more

Andrei Maiseyeu, PhD, is an Associate Professor at Case Western Reserve University in the Department of Medicine (School of Medicine) and the Department of Biomedical Engineering (Case School of Engineering). His research focuses on developing nanotechnology tools for diagnosing and treating cardiometabolic diseases such as atherosclerosis, type 2 diabetes, and obesity. He has pioneered contrast agents for MRI of cardiovascular disease and investigates mechanisms of inflammation-driven metabolic disorders. Dr. Maiseyeu's lab integrates drug delivery systems, imaging probe engineering, and molecular biology to address residual risk in atherosclerosis and environmental nanoparticle toxicity. Education : PhD in Organic Chemistry, Lomonosov Moscow State University (2007) MSc and BSc in Chemistry, Lomonosov Moscow State University (2002) Research Interests : His work encompasses: Nanoparticle-mediated drug delivery and imaging Lipoprotein biology and immunometabolism Environmental pollution-induced cardiovascular pathologies GLP-1 receptor agonist therapies for cardiovascular disease Cardiac gene therapy using engineered nanoparticles Grants & Funding : Supported by NIH grants, industry partnerships, and foundations like the Alzheimer’s Association. His lab has trained over 25 students and postdocs, many now in academic and industrial roles. Labs & Collaborations : Leads the Maiseyeu Lab at Case Western Reserve University, collaborating with institutions like The Ohio State University and the University of Maryland.